By Professor Jason Grebely

Journal articles

Martinello M; Grebely J; Matthews GV, 2017, 'Direct-acting antivirals for acute HCV: how short can we go?', Lancet Gastroenterology and Hepatology, 2, pp. 316 - 318, http://dx.doi.org/10.1016/S2468-1253(17)30043-2

Martinello M; Grebely J; Petoumenos K; Gane E; Hellard M; Shaw D; Sasadeusz J; Applegate TL; Dore GJ; Matthews GV, 2017, 'HCV reinfection incidence among individuals treated for recent infection', Journal of Viral Hepatitis, 24, pp. 359 - 370, http://dx.doi.org/10.1111/jvh.12666

Eslam M; McLeod D; Kelaeng KS; Mangia A; Berg T; Thabet K; Irving WL; Dore GJ; Sheridan D; Grønbæk H; Abate ML; Hartmann R; Bugianesi E; Spengler U; Rojas A; Booth DR; Weltman M; Mollison L; Cheng W; Riordan S; Mahajan H; Fischer J; Nattermann J; Douglas MW; Liddle C; Powell E; Romero-Gomez M; George J; Metwally M; White R; Gallego-Duran R; Leung R; Mahajan N; Bassendine M; Rahme A; Rosso C; Mezzabotta L; Malik B; Matthews G; Asimakopoulos A; Applegate T; Grebely J; Fragomeli V; Jonsson JR; Santoro R, 2017, 'IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis', Nature Genetics, 49, pp. 795 - 800, http://dx.doi.org/10.1038/ng.3836

Morris MD; Shiboski S; Bruneau J; Hahn JA; Hellard M; Prins M; Cox AL; Dore G; Grebely J; Kim AY; Lauer GM; Lloyd A; Rice T; Shoukry N; Maher L; Page K, 2017, 'Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: The InC3 collaboration', Clinical Infectious Diseases, 64, pp. 860 - 869, http://dx.doi.org/10.1093/cid/ciw869

Haber B; Gane E; Dore GJ; Grebely J; Altice F; Litwin AH; Dalgard O; Shibolet O; Luetkemeyer A; Nahass R; Peng C-Y; Conway B; Iser DM; Huang H-C; Gendrano IN; Kelly M; Hwang P; Robertson M; Wahl J; Barr E; Platt HL, 2017, 'HEPATITIS C VIRUS (HCV) REINFECTION AND INJECTION RISK BEHAVIOR FOLLOWING ELBASVIR/GRAZOPREVIR (EBR/GZR) TREATMENT IN PATIENTS ON OPIOID AGONIST THERAPY (OAT): CO-STAR THREE-YEAR FOLLOW-UP STUDY', GASTROENTEROLOGY, 152, pp. S1058 - S1059, http://dx.doi.org/10.1016/S0016-5085(17)33575-8

Rodrigo C; Walker MR; Leung P; Eltahla AA; Grebely J; Dore GJ; Applegate T; Page K; Dwivedi S; Bruneau J; Morris MD; Cox AL; Osburn W; Kim AY; Schinkel J; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Luciani F; Lloyd AR; Bull RA, 2017, 'Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection', Infection Genetics and Evolution, 49, pp. 88 - 96, http://dx.doi.org/10.1016/j.meegid.2017.01.006

Grebely J; Dore GJ, 2017, 'Treatment of HCV in persons who inject drugs: Treatment as prevention', Clinical Liver Disease, 9, pp. 77 - 80, http://dx.doi.org/10.1002/cld.626

Blach S; Zeuzem S; Manns M; Altraif I; Duberg AS; Muljono DH; Waked I; Alavian SM; Lee MH; Negro F; Abaalkhail F; Abdou A; Abdulla M; Abou Rached A; Aho I; Akarca U; Al Ghazzawi I; Al Kaabi S; Al Lawati F; Al Namaani K; Al Serkal Y; Al-Busafi SA; Al-Dabal L; Aleman S; Alghamdi AS; Aljumah AA; Al-Romaihi HE; Andersson MI; Arendt V; Arkkila P; Assiri AM; Baatarkhuu O; Bane A; Ben-Ari Z; Bergin C; Bessone F; Bihl F; Bizri AR; Blachier M; Blasco AJ; Brandao Mello CE; Bruggmann P; Brunton CR; Calinas F; Chan HLY; Chaudhry A; Cheinquer H; Chen CJ; Chien RN; Choi MS; Christensen PB; Chuang WL; Chulanov V; Cisneros L; Clausen MR; Cramp ME; Craxi A; Croes EA; Dalgard O; Daruich JR; De Ledinghen V; Dore GJ; El-Sayed MH; Ergor G; Esmat G; Estes C; Falconer K; Farag E; Ferraz MLG; Ferreira PR; Flisiak R; Frankova S; Gamkrelidze I; Gane E; Garcia-Samaniego J; Khan AG; Gountas I; Goldis A; Gottfredsson M; Grebely J; Gschwantler M; Guimaraes Pessoa M; Gunter J; Hajarizadeh B; Hajelssedig O; Hamid S; Hamoudi W; Hatzakis A; Himatt SM; Hofer H; Hrstic I; Hui YT; Hunyady B; Idilman R; Jafri W; Jahis R; Janjua NZ; Jarčuška P; Jeruma A; Jonasson JG, 2017, 'Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study', Lancet Gastroenterology and Hepatology, 2, pp. 161 - 176, http://dx.doi.org/10.1016/S2468-1253(16)30181-9

Eltahla AA; Leung P; Pirozyan MR; Rodrigo C; Grebely J; Applegate T; Maher L; Luciani F; Lloyd AR; Bull RA, 2017, 'Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment', Scientific Reports, 7, pp. 41719, http://dx.doi.org/10.1038/srep41719

Eltahla AA; Rodrigo C; Betz-Stablein B; Grebely J; Applegate T; Luciani F; Schinkel J; Dore GJ; Page K; Bruneau J; Morris MD; Cox AL; Kim AY; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Lloyd AR; Bull RA, 2017, 'Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents', Journal of Viral Hepatitis, 24, pp. 37 - 42, http://dx.doi.org/10.1111/jvh.12615

Hajarizadeh B; Grebely J; McManus H; Estes C; Razavi H; Gray RT; Alavi M; Amin J; McGregor S; Sievert W; Thompson A; Dore GJ, 2017, 'Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment', Journal of Gastroenterology and Hepatology Australia, 32, pp. 229 - 236, http://dx.doi.org/10.1111/jgh.13453

Fortier E; Alavi M; Bruneau J; Micallef M; Perram J; Sockalingam S; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Grebely J, 2017, 'Depression, Anxiety, and Stress among People with Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia', Journal of Addiction Medicine, 11, pp. 10 - 18, http://dx.doi.org/10.1097/ADM.0000000000000261

Grebely J; Dore GJ; Morin S; Rockstroh JK; Klein MB, 2017, 'Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there', Journal of the International AIDS Society, 20, pp. 22146, http://dx.doi.org/10.7448/IAS.20.1.22146

Rodrigo C; Eltahla AA; Bull RA; Luciani F; Grebely J; Dore GJ; Applegate T; Page K; Bruneau J; Morris MD; Cox AL; Osburn W; Kim AY; Shoukry NH; Lauer GM; Maher L; Schinkel J; Prins M; Hellard M; Lloyd AR, 2017, 'Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study', Journal of Viral Hepatitis, 24, pp. 43 - 52, http://dx.doi.org/10.1111/jvh.12616

Bartlett SR; Grebely J; Eltahla AA; Reeves JD; Howe AYM; Miller V; Ceccherini-Silberstein F; Bull RA; Douglas MW; Dore GJ; Harrington P; Lloyd AR; Jacka B; Matthews GV; Wang GP; Pawlotsky JM; Feld JJ; Schinkel J; Garcia F; Lennerstrand J; Applegate TL, 2017, 'Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review', Hepatology Communications, 1, pp. 379 - 390, http://dx.doi.org/10.1002/hep4.1050

Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ, 2017, 'Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014)', Hepatology Communications, 1, pp. 736 - 747, http://dx.doi.org/10.1002/hep4.1073

Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop AJ; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer CM; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2017, 'Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study', Journal of Hepatology, 66, pp. S513 - S513, http://dx.doi.org/10.1016/s0168-8278(17)31428-9

Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2017, 'O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study', Journal of Virus Eradication, 3, pp. 5 - 5, http://dx.doi.org/10.1016/s2055-6640(20)30896-7

Dore G; Grebely J; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Iser DM; Huang HC; Gendrano IN; Kelly M; Hwang P; Robertson M; Wahl J; Barr E; Platt HL, 2017, 'O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study', Journal of Virus Eradication, 3, pp. 8 - 8, http://dx.doi.org/10.1016/s2055-6640(20)30904-3

Alavi M; Amin J; Grebely J; Law MG; Janjua NZ; Krajden M; Hajarizadeh B; George J; Matthews GV; Larney S; Degenhardt L; Dore GJ, 2017, 'O23 Characterisation of populations with hepatitis C to improve access to antiviral therapy programs: a population-based linkage study', Journal of Virus Eradication, 3, pp. 9 - 9, http://dx.doi.org/10.1016/s2055-6640(20)30906-7

Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Lloyd AR; Dore GJ, 2017, 'O6 Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the StoP-C study', Journal of Virus Eradication, 3, pp. 2 - 3, http://dx.doi.org/10.1016/s2055-6640(20)30889-x

Iversen J; Grebely J; Catlett B; Cunningham P; Dore GD; Maher L, 2017, 'O9 Progress towards elimination: rapid uptake of HCV treatment among people who inject drugs following broad access to DAA therapies', Journal of Virus Eradication, 3, pp. 4 - 4, http://dx.doi.org/10.1016/s2055-6640(20)30892-x

Cunningham E; Amin J; Bretana NA; Luciani F; Degenhardt L; Larney S; Hajarizadeh B; Dore GJ; Lloyd A; Grebely J, 2017, 'P10 Injecting risk behaviours among people who inject drugs in an Australian prison setting, 2005–2014: the HITS-p study', Journal of Virus Eradication, 3, pp. 15 - 16, http://dx.doi.org/10.1016/s2055-6640(20)30751-2

Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2017, 'P20 Monitoring the uptake of hepatitis C: direct acting antiviral treatment in Australia', Journal of Virus Eradication, 3, pp. 19 - 19, http://dx.doi.org/10.1016/s2055-6640(20)30761-5

Bajis S; Lamoury F; Applegate TL; Maher L; Treloar C; Mowat Y; Schulz M; Hajarizadeh B; Marshall A; Cunningham E; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Dore GJ; Grebely J, 2017, 'P4 Acceptability of point of care finger-stick and venepuncture hepatitis C virus testing among people who inject drugs and homeless people', Journal of Virus Eradication, 3, pp. 13 - 14, http://dx.doi.org/10.1016/s2055-6640(20)30745-7

Bartlett SR; Applegate T; Jacka B; Lamoury F; Bull R; Danta M; Bradshaw D; Lloyd AR; Hellard M; Dore GJ; Matthews GV; Grebely J, 2017, 'P6 Phylogenetic clustering of recent hepatitis C virus infection between 2004 and 2015', Journal of Virus Eradication, 3, pp. 14 - 15, http://dx.doi.org/10.1016/s2055-6640(20)30747-0

Grebely J; Jacobson IM; Kayali Z; Verna EC; Shiffman ML; Hyland RH; Stamm LM; Huang KC; Brainard DM; McHutchison JG; Pol S; Chung RT; Bernstein DE; Dore G, 2017, 'SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy', Journal of Hepatology, 66, pp. S513 - S514, http://dx.doi.org/10.1016/s0168-8278(17)31429-0

Grebely J; Mauss S; Brown A; Bronowicki JP; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ, 2016, 'Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials', Clinical Infectious Diseases, 63, pp. 1405 - 1411, http://dx.doi.org/10.1093/cid/ciw580

Grebely J; Dore GJ; Zeuzem S; Aspinall RJ; Fox R; Han L; McNally J; Osinusi A; Brainard DM; Subramanian GM; Natha M; Foster GR; Mangia A; Sulkowski M; Feld JJ, 2016, 'Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials', Clinical Infectious Diseases, 63, pp. 1479 - 1481, http://dx.doi.org/10.1093/cid/ciw579

Sheridan DA; Hajarizadeh B; Fenwick FI; Matthews GV; Applegate T; Douglas M; Neely D; Askew B; Dore GJ; Lloyd AR; George J; Bassendine MF; Grebely J, 2016, 'Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection', Liver International, 36, pp. 1774 - 1782, http://dx.doi.org/10.1111/liv.13176

Martinello M; Gane E; Hellard M; Sasadeusz J; Shaw D; Petoumenos K; Applegate T; Grebely J; Maire L; Marks P; Dore GJ; Matthews GV; Cooper D, 2016, 'Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study', Hepatology, 64, pp. 1911 - 1921, http://dx.doi.org/10.1002/hep.28844

Tsui JI; Mirzazadeh A; Hahn JA; Maher L; Bruneau J; Grebely J; Hellard M; Kim AY; Shoukry NH; Cox AL; Prins M; Dore GJ; Lauer G; Lloyd AR; Page K, 2016, 'The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males', Drug and Alcohol Dependence, 169, pp. 156 - 162, http://dx.doi.org/10.1016/j.drugalcdep.2016.10.024

Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ; Han A, 2016, 'Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014)', Journal of Hepatology, 65, pp. 1086 - 1093, http://dx.doi.org/10.1016/j.jhep.2016.08.010

Dore GJ; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Grebely J; Howe AYM; Gendrano IN; Chen E; Huang HC; Dutko FJ; Nickle DC; Nguyen BY; Wahl J; Barr E; Robertson MN; Platt HL, 2016, 'Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy a randomized trial', Annals of Internal Medicine, 165, pp. 625 - 634, http://dx.doi.org/10.7326/M16-0816

Rodrigo C; Eltahla AA; Bull RA; Grebely J; Dore GJ; Applegate T; Page K; Bruneau J; Morris MD; Cox AL; Osburn W; Kim AY; Schinkel J; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Estes C; Razavi H; Lloyd AR; Luciani F, 2016, 'Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia', Journal of Infectious Diseases, 214, pp. 1383 - 1389, http://dx.doi.org/10.1093/infdis/jiw389

Alavi M; Law MG; Grebely J; Amin J; Hajarizadeh B; George J; Dore GJ; Han A, 2016, 'Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study', Journal of Hepatology, 65, pp. 879 - 887, http://dx.doi.org/10.1016/j.jhep.2016.06.025

Janjua NZ; Kuo M; Yu A; Alvarez M; Wong S; Cook D; Wong J; Grebely J; Butt ZA; Samji H; Ramji A; Tyndall M; Krajden M, 2016, 'The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC)', Ebiomedicine, 12, pp. 189 - 195, http://dx.doi.org/10.1016/j.ebiom.2016.08.035

Thabet K; Asimakopoulos A; Shojaei M; Romero-Gomez M; Mangia A; Irving WL; Berg T; Dore GJ; Grønbæk H; Sheridan D; Abate ML; Bugianesi E; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Spengler U; Nattermann J; Wahid A; Rojas A; White R; Douglas MW; McLeod D; Powell E; Liddle C; Van Der Poorten D; George J; Eslam M; Gallego-Duran R; Applegate T; Bassendine M; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Grebely J; Fragomeli V; Jonsson JR; Santaro R, 2016, 'MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C', Nature Communications, 7, pp. 12757, http://dx.doi.org/10.1038/ncomms12757

Grebely J; Litwin A; Dore GJ, 2016, 'Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all', Journal of Viral Hepatitis, 23, pp. 664 - 666, http://dx.doi.org/10.1111/jvh.12550

Montoya V; Olmstead A; Tang P; Cook D; Janjua N; Grebely J; Jacka B; Poon AFY; Krajden M, 2016, 'Deep sequencing increases hepatitis C virus phylogenetic cluster detection compared to Sanger sequencing', Infection Genetics and Evolution, 43, pp. 329 - 337, http://dx.doi.org/10.1016/j.meegid.2016.06.015

Eslam M; Mangia A; Berg T; Chan HLY; Irving WL; Dore GJ; Abate ML; Bugianesi E; Adams LA; Najim MAM; Miele L; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Romero-Gomez M; Spengler U; Nattermann J; Rahme A; Sheridan D; Booth DR; McLeod D; Powell E; Liddle C; Douglas MW; van der Poorten D; George J; White R; Rojas A; Gallego-Duran R; Bassendine M; Wong VWS; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Applegate T; Grebely J; Fragomeli V; Jonsson JR; Santaro R, 2016, 'Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes', Hepatology, 64, pp. 34 - 46, http://dx.doi.org/10.1002/hep.28475

Martin NK; Vickerman P; Dore GJ; Grebely J; Miners A; Cairns J; Foster GR; Hutchinson SJ; Goldberg DJ; Martin TCS; Ramsay M; Hickman M, 2016, 'Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation', Journal of Hepatology, 65, pp. 17 - 25, http://dx.doi.org/10.1016/j.jhep.2016.02.007

Lamoury FMJ; Hajarizadeh B; Keoshkerian E; Feld JJ; Amin J; Teutsch S; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Applegate TL; Grebely J; Dolan K, 2016, 'HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection', BMC Infectious Diseases, 16, pp. 241, http://dx.doi.org/10.1186/s12879-016-1567-2

Doyle JS; Grebely J; Spelman T; Alavi M; Matthews GV; Thompson AJ; Dore GJ; Hellard ME; Kaldor J; Marks P; Lloyd A; Haber P; French R; White P; Rawlinson W; Day C; Van Beek I; McCaughan G; Madden A; Dolan K; Farrell G; Crofts N; Sievert W; Baker D, 2016, 'Quality of life and social functioning during treatment of recent hepatitis C infection: A multi-centre prospective cohort', Plos One, 11, pp. e0150655, http://dx.doi.org/10.1371/journal.pone.0150655

Bourgeois S; Grebely J; Dore GJ; Aspinall R; Rodriguez-Torres M; Fox R; Sulkowski M; Feld JJ; Carr V; Liu L; Ding X; McNally J; Osinusi A; Brainard DM; Subramanian M, 2016, 'SOF/VEL for 12 weeks is well tolerated and results in high SVR12 rates in people receiving opioid substitution therapy', HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, 18, pp. 16 - 16

Jacka B; Applegate T; Poon AF; Raghwani J; Harrigan PR; Debeck K; Milloy MJ; Krajden M; Olmstead A; Joy JB; Marshall BDL; Hayashi K; Pybus OG; Lima VD; Magiorkinis G; Montaner J; Lamoury F; Dore GJ; Wood E; Grebely J, 2016, 'Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada', Journal of Hepatology, 64, pp. 1247 - 1255, http://dx.doi.org/10.1016/j.jhep.2016.02.031

MacParland SA; Fadel SM; Mihajlovic V; Fawaz A; Kim C; Nur-Ur Rahman AKM; Liu J; Kaul R; Kovacs C; Grebely J; Dore GJ; Wong DK; Ostrowski MA, 2016, 'HCV specific IL-21 producing T cells but not IL-17A producing T cells are associated with HCV viral control in HIV/HCV coinfection', Plos One, 11, pp. e0154433, http://dx.doi.org/10.1371/journal.pone.0154433

Hajarizadeh B; Lamoury FMJ; Feld JJ; Amin J; Keoshkerian E; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Grebely J; Applegate TL, 2016, 'Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection', Virology Journal, 13, pp. 32, http://dx.doi.org/10.1186/s12985-016-0482-x

Grebely J; Dore GJ; Greenwald R; Swan T; Barua S; Taylor LE, 2016, 'Hepatitis c virus treatment and persons who inject drugs', Annals of Internal Medicine, 164, pp. 203, http://dx.doi.org/10.7326/L15-0485

Grebely J; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Phung N; Weltman MD; Day CA; Treloar C; Bath N; Haber PS; Dore GJ, 2016, 'Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: The ETHOS Study', Addiction, 111, pp. 311 - 319, http://dx.doi.org/10.1111/add.13197

Back to profile page